Nuclear Medicine Market Worth USD 15.8 Million by 2025 | CAGR of 10.1%

The MarketWatch News Department was not involved in the creation of this content.

Dec 03, 2020 (Heraldkeepers) —
The latest report pertaining to ‘Nuclear Medicine Market’ provides a detailed analysis regarding market size, revenue estimations and growth rate of the industry. In addition, the report illustrates the major obstacles and newest growth strategies adopted by leading manufacturers who are a part of the competitive landscape of this market.

Nuclear Medicine Market is valued at USD 8.12 Million in 2018 and expected to reach USD 15.8 Million by 2025 with CAGR of 10.1% over the forecast period.

Get Sample Copy of This Premium Report https://brandessenceresearch.com/requestSample/PostId/406

**The sample pages of this report is immediately accessible on-demand.**

Top Nuclear Medicine Companies

Nuclear Medicine Market Report covers prominent players are like,

  • Bracco Imaging S.P.A.
  • Cambridge Isotope Laboratories, Inc
  • Cardinal Health, Inc.
  • Covidien, Plc
  • Eczacibasi-Monrol
  • Fujifilm Holdings Corporation
  • GE Healthcare (Subsidiary Of General Electric Company)
  • IBA Group
  • Isotec, Ntp Radioisotopes (Pty), Ltd
  • Siemens Healthcare (Subsidiary Of Siemens AG)
  • Taiyo Nippon Sanso Corporation
  • Urenco Limited
  • Rotem Industries, Ltd., Inc.

Nuclear Medicine Market report is segmented on the basis of type, procedural volumes, application, end-user and regional & country level. Based upon type, nuclear medicine market is classified as diagnostic nuclear medicine, therapeutic nuclear medicine, research nuclear medicine and other. Based upon procedural volumes, nuclear medicine market is classified into diagnostic procedures, therapeutic procedures and other. Based upon application, nuclear medicine market is classified into oncology, cardiology, neurology, thyroid, lymphoma, endocrinology and other. Based upon end-user, nuclear medicine market is classified into diagnostic centers, hospitals, research centers and other.

Market Analysis of Nuclear Medicine-

Nuclear medicine is involving the application of radioactive substances in the diagnosis and treatment of various diseases. Nuclear Medicine images can support the physician in diagnosing of many diseases and conditions such as analyze kidney and spleen function, image blood flow and function of the heart and scan the lungs for respiratory and blood-flow problems. Nuclear medicine uses radioactive materials helps to diagnose and treat a wide variety of diseases and disorders. It provides unique information about the human body and health. Nowadays nuclear medicine is expected to be the most sensitive approach to measure in vivo physiology, biochemistry and metabolism. The future development of nuclear medicine depends on an infrastructure of physics, mathematics and chemical biology.

The regions covered in this Global Nuclear Medicine market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, market of Nuclear Medicine is sub divided into U.S., Mexico, Canada, UK, France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Global Nuclear Medicine market Report covers prominent players are like Bracco Imaging S.P.A., Cambridge Isotope Laboratories, Inc., Cardinal Health, Inc., Covidien, Plc, Eczacibasi-Monrol, Fujifilm Holdings Corporation, GE Healthcare (Subsidiary Of General Electric Company), IBA Group, Isotec, Ntp Radioisotopes (Pty), Ltd., Siemens Healthcare (Subsidiary Of Siemens AG), Taiyo Nippon Sanso Corporation, Urenco Limited, Rotem Industries, Ltd., Inc. and others.

Increasing prevalence of anxiety and diagnosis of various

Read more

Nuclear Medicine/ Radiopharmaceuticals Market 2020 | Industry Trends, Growth Drivers, Competitive Landscape, Regional Analysis 2026

The MarketWatch News Department was not involved in the creation of this content.

Dec 04, 2020 (The Expresswire) —
The global “Nuclear Medicine/Radiopharmaceuticals Market” size is projected to reach USD 9.67 billion by 2026. According to a report published by Fortune Business Insights, titled “Nuclear Medicine/Radiopharmaceuticals Market Size, Share and Industry Analysis, By Type (Diagnostic Radiopharmaceuticals, Therapeutic Radiopharmaceuticals), By Application (Neurology, Cardiology, Oncology, and Others), By End User (Hospitals and Clinics, Diagnostic Centres, and Others) and Regional Forecast, 2019-2026,” the market was valued at USD 4.86 billion in 2018. Driven by increasing number of successful clinical trials, the market will exhibit a CAGR of 9.2% from 2019-2026.

Leading Players operating in the Nuclear Medicine/ Radiopharmaceuticals Market are:

Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:

  • Lantheus Medical Imaging, Inc.
  • Cardinal Health
  • Norgine B.V.
  • Curium
  • Advanced Accelerator Applications (Novartis AG)
  • Bracco Diagnostic Inc.
  • Jubilant Life Sciences Limited
  • Bayer AG
  • Eli Lilly and Company
  • GE Healthcare (General Electric Company)

Request a Sample Copy of the Research Report:https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/nuclear-medicine-radiopharmaceuticals-market-101812

Radiopharmaceuticals are substances that are used to diagnose specific medical problems or diseases. Increasing imaging capabilities and efficiencies have led to a wide product adoption across the world. Increasing number of successful clinical trials associated with radiopharmaceuticals will fuel the demand for the product. Recent drug application area discoveries have showcased promise for the companies operating in the market. Technological advancements in nuclear imaging and their applications in diagnosis of cancer and other serious diseases have opened up a huge potential for growth. Growing awareness regarding the adverse effects of chronic diseases, and the need for early diagnosis will aid market growth.

The advancements in imaging systems have played a major role in the growth of the market. Companies are putting in increased efforts towards the manufacturing of diagnostic radiopharmaceuticals. Increasing investments in the research and development (RandD) will create several growth opportunities for market growth. At the same instance, therapeutic radiopharmaceuticals can be used for the treatment of critical illnesses such as cancers.

Have Any Query? Ask Our Experts:https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/nuclear-medicine-radiopharmaceuticals-market-101812

Detailed Table of Content:

  • Introduction
    • Research Scope
    • Market Segmentation
    • Research Methodology
    • Definitions and Assumptions
  • Executive Summary
  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Key Insights
    • Installed Base of PET/PET-CT Scanners For Key Countries, 2015 and 2018
    • Installed Base of Gamma Cameras for Key Countries, 2018
    • PET/PET-CT Procedure Volume for Key Countries, 2018
    • Reimbursement Scenario in Key Countries
    • New Product Launches
    • Key Industry Developments
    • Pipeline Analysis
  • Global Nuclear Medicine/ Radiopharmaceuticals Market Analysis, Insights and Forecast, 2015-2026
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast By Type
      • Diagnostic Radiopharmaceuticals
        • PET Radiopharmaceuticals
          • FDG-PET/18F
          • 68Ga
          • 68Cu
          • 11C
          • Others
        • SPECT Radiopharmaceuticals
          • Technetium-99m
          • Iodine-123
          • Xenon-133
          • Thallium-201
          • Others
        • Therapeutic Radiopharmaceuticals
      • Market Analysis, Insights and Forecast By Application
        • Neurology
        • Cardiology
        • Oncology
        • Others
      • Market Analysis, Insights and Forecast By End User
        • Hospitals and Clinics
        • Diagnostic Centers
        • Others
      • Market Analysis, Insights and Forecast By Region
        • North
Read more

Nuclear Medicine Market Research Report by Product, by Application – Global Forecast to 2025 – Cumulative Impact of COVID-19 – Press Release

New York, Dec. 01, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Nuclear Medicine Market Research Report by Product, by Application – Global Forecast to 2025 – Cumulative Impact of COVID-19” – https://www.reportlinker.com/p05993422/?utm_source=GNW

The Global Nuclear Medicine Market is expected to grow from USD 3,812.67 Million in 2019 to USD 5,701.38 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 6.93%.

Market Segmentation & Coverage:
This research report categorizes the Nuclear Medicine to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Product, the Nuclear Medicine Market studied across Diagnostic Products and Therapeutic Products. The Diagnostic Products further studied across PET and SPECT. The Therapeutic Products further studied across Alpha Emitters, Beta Emitters, and Brachytherapy.

Based on Application, the Nuclear Medicine Market studied across Bone Metastasis, Cardiology, Endocrine Tumor, Lymphoma, Oncology, and Thyroid.

Based on Geography, the Nuclear Medicine Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Nuclear Medicine Market including Australian Nuclear Science & Technology Organization (ANSTO), Bracco Imaging S.p.A, Curium Pharma, Eckert & Ziegler, Eczacibasi-Monrol, GE Healthcare, Jubilant Pharma. LLC, Lantheus Medical Imaging, Inc., Mallinckrodt, Nordion (Canada) Inc., NTP Radioisotopes SOC Ltd., and The Institute for Radioelements (IRE – IRE ELiT).

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Nuclear Medicine Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces,

Read more

IAEA and French Society of Nuclear Medicine Sign Practical Arrangements to Promote Collaboration in Nuclear Medicine

The PAs provide a framework for collaboration in the area of capacity building for nuclear medicine and molecular imaging, or any allied disciplines, particularly for professionals from French-speaking countries. (Photo: D. Calma/IAEA)

The finalization and signing of these PAs are the latest development in a shared history of successful collaboration between the Agency and the SFMN which stretches back more than a decade.

In recent years the SFMN has invited IAEA experts to participate in its Annual Meetings and helped to host and place IAEA fellows into clinical and scientific research centres across France. In particular, the SFMN trained five African fellows in 2017, through the National Institute for Nuclear Science and Technology (INSTN) platform.

Additionally, the SFMN has supported the IAEA’s technical cooperation programme through the identification of French-speaking experts and cost-free experts, who in turn have supported Africa Member States as they draft and subsequently adopt clinical protocols for expanding the scope of nuclear medicine services and capabilities.

The Practical Arrangements will provide new opportunities to not only strengthen nuclear medicine capacities in the region, but to establish new collaborative avenues in other, related support areas for nuclear medicine, such as mentorship, networking, building remote or virtual training systems, the use and development of software platforms and data management.

Source Article

Read more

Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2030 – Focus on the Supply Chain Model of Medical Isotope Mo-99 (Tc-99m)

DUBLIN, Oct. 21, 2020 /PRNewswire/ — The “Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030” report has been added to ResearchAndMarkets.com’s offering.

The ‘Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030’ report provides a detailed study on the current market landscape and future potential of the companies having the capabilities to manufacture radiopharmaceuticals. In addition, the study features an in-depth analysis, highlighting the capabilities of a diverse set of industry stakeholders.

Over the years, medical research teams across the world have gradually tapped into the vast potential of radiopharmaceuticals and nuclear medicines. In fact, the technology that is now used in this field is reported to have witnessed significant evolution, in terms of technological sophistication. As a result, the demand for such specialized chemicals has grown at an exponential rate.

However, the development and production of radiopharmaceuticals is inherently complex, and requires specialized facilities and operational expertise. Therefore, acquiring the necessary technical acumen and infrastructure to support such operations is not a feasible option for pharmaceutical companies, owing to a number of associated clauses and concerns (such as need for high capital investments, unique operating licenses and compliance to special regulatory requirements).

Scope Of the Report

  • A detailed assessment of the current market landscape with respect to the players (industry and non-industry) involved in manufacturing radiopharmaceuticals. It features information on the year of establishment, company size, purpose of production (fulfilling in-house requirements / for contract services), location of headquarters, location of manufacturing facilities, scale of production, applications of radiopharmaceuticals (in diagnosis, therapeutics and theranostics), type of diagnostic radiopharmaceuticals (PET and SPECT), type of therapeutic radiopharmaceuticals (alpha emitters, beta emitters and others), target therapeutic area (cardiology, oncology, neurology, thyroid and others) and services offered.
  • An insightful four-dimensional comparison of the radiopharmaceutical manufacturers, based on supplier power (year of establishment), product portfolio (number of isotopes being manufactured for various applications targeting different therapeutic areas) of the manufacturer, scale at which they manufacture their respective products and company size.
  • Tabulated profiles of key industry players based in North America, Europe and Asia-Pacific (shortlisted based on the company size of the players), featuring a brief overview of the company, a list of products and manufacturing facilities, recent developments and an informed future outlook.
  • An analysis of recent partnerships and collaborations inked in this domain since 2017, based on several parameters, such as the type of partnership, year of partnership, type of radioisotope involved, therapeutic area mentioned in the agreement, application of the radioisotope mentioned in the agreement, and a schematic representation showcasing the players that have forged the maximum number of alliances. Furthermore, we have provided a world map representation of the deals inked in this field, highlighting those that have been established within and across different continents.
  • A detailed discussion on the supply chain model of medical isotope Mo-99 (Tc-99m), highlighting the main steps of the supply chain, from irradiation of uranium targets in nuclear research reactors to the administration of Tc-99m to patients. Along with this, it describes the structure of the
Read more